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a b s t r a c t
Evans syndrome (ES) is a rare hematological disease characterized by autoimmune hemo-
lytic anemia, immune thrombocytopenia, and/or neutropenia, all of which may be seen
simultaneously or subsequently. Thrombotic events in ES are uncommon. Furthermore,
non-ST segment-elevationmyocardial infarction (NSTEMI) during ES is a very rare condition.
Here, we describe a case of a 69-year-old female patient presenting with NSTEMI and ES.
Revascularization via percutaneous coronary intervention (PCI) was scheduled and per-
formed. Hemopericardium and cardiac tamponade occurred 5 h after PCI, and urgent
pericardiocentesis was performed. Follow-up was uneventful, and the patient was safely
discharged. Early recognition and appropriate management of NSTEMI is crucial to prevent
morbidity and mortality. Coexistence of NSTEMI and ES, which is associated with increased
bleeding risk, is a challenging scenario and these patients should be closely monitored in
order to achieve early recognition and treatment of complications.
# 2015 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionEvans syndrome (ES) is a rare hematological disease charac-
terized by autoimmune hemolytic anemia (AIHA), immune
thrombocytopenia (ITP), and/or neutropenia, all of which may
be seen simultaneously or subsequently with no known
underlying etiology.1 Despite various treatment options, ES
is associated with signiﬁcant morbidity and mortality rates
due to chronic and repetitive nature of the disease.2* Corresponding author.
E-mail address: ﬁlizkizilirmak@hotmail.com (F. Kizilirmak).
http://dx.doi.org/10.1016/j.ihj.2015.11.041
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Antibodies against erythrocytes, platelets, and neutro-
phils are present in ES. While some of the antibodies are
directed against a base protein of the Rh blood group and
cause redblooddestruction,most of themaredirectedagainst
the platelet GPIIb/IIIa.3 Although most of the cases are
classiﬁed as primary (or idiopathic), ES has been associated
with several conditions including systemic lupus erythema-
tosus, lymphoproliferative disorders, and primary immuno-
deﬁciency diseases as secondary.2 Thrombotic events are
rarely seen in ES; thus, anecdotal case reports exist mostly asB.V. This is an open access article under the CC BY-NC-ND license
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patients, 6 patients (21%) developed cardiovascular events
during a follow-up of 4.8 years. One patient developed
myocardial infarction, 4 developed acute coronary syndrome,
and 1 developed stroke. 21%had cardiovascular events and 16
patients died.8
The present case exhibits coexisting ES and non-ST
segment-elevationmyocardial infarction (NSTEMI) complicat-
ed with hemopericardium, a phenomenon which has been
reported as a very rare condition.
2. Case reportA69-year-old female patientwas admitted to emergency room
for chest painwith increasing intensity for the past 1week. She
had history of hypertension treated with metoprolol (50 mg/
day) for 10 years and umbilical hernia surgery 5 years ago. On
examination, she was sweating, had mild dyspnea and
paleness. Her blood pressure was 135/82 mmHg and heart
rate was 102 beats/min with a blood saturation of 96% in room
air. Physical examination was unremarkable except the
relapsed umbilical hernia. She was a non-smoker and did
not consume alcohol. Her 12-lead electrocardiogram (ECG)
showed ST-segment depression in leads V3–V6.
Echocardiographic examination revealed a left ventricular
ejection fraction of 55% with hypokinesia in inferior and
posterior segments, left ventricular hypertrophy, and moder-
ate mitral regurgitation.
Initial blood tests showed white blood cell count (WBC)
2.86  103/mL (normal range 4.4–11.3  103/mL), hemoglobin
6 g/dL (normal range 11.7–16.1 g/dL), platelet count 1  103/mL
(normal range 152–396  103/mL), urea 35 mg/dL (normal range
16.6–48.5 mg/dL), creatinine 1 mg/dL (normal range 0.5–
0.9 mg/dL), glucose 83.5 mg/dL (normal range 74–109 mg/dL),
sodium 130 mmol/L (normal range 136–145 mmol/L), potassi-
um 4.3 mmol/L (normal range 3.5–5.1 mmol/L), prothrombin
time 13.2 s (normal range 11.5–15 s), activated partial throm-
boplastin time 31 s (normal range 26–32 s), and international
normalized ratio 1.0 (normal range 0.8–1.2). Repeated complete
blood count (CBC) provided similar results. Peripheral smear
test was unremarkable.We detected levels of cardiac enzymes
as follows: CK 157 (normal range 26–192 U/L), CK-MB 11
(normal range <7.2 mg/L), and Tn-I 0.29 mg/L (normal range
<0.023 mg/L).[(Fig._1)TD$FIG]
Fig. 1 – Coronary angiographThe patient received immediate treatment with a loading
dose of clopidogrel (300 mg) and ASA (300 mg), and was
transferred to our coronary intensive care unit (CICU) with the
diagnosis of acute NSTEMI and pancytopenia. Intravenous
nitroglycerin infusion was initiated for the relief of her chest
pain. She also received 100 mg/day metoprolol and 40 mg/day
statin via oral route.
Hematology department was consulted for the patient, and
further tests showed high levels of LDH 366 U/L (normal 135–
214 U/L), low levels of haptoglobulin <10 (normal 30–200 mg/
dL), and positive Direct and Indirect Coombs tests. ES was
diagnosed in this patient with respect to neutropenia, AIHA,
and thrombocytopenia. Two units of packed red blood cells
and 8 units of thrombocyte suspension were transfused.
Intravenousmethyl prednisolone at a dose of 1 mg/kg/day and
intravenous immunoglobulin (IVIG) 1 mg/kg/day were admin-
istered for 2 days.
On the second day of admission, CBC revealed WBC 9.81 
103/mL, hemoglobin 7.2 g/dL, and platelet count 52 103/mL.
Again, 2 units of packed red-blood cells were transfused.
Because of refractory angina despite optimal medical
treatment, urgent conventional coronary angiography (CCA)
was scheduled and performed with radial access with 60 U/kg
unfractionated heparin (UFH). CCA demonstrated 99% ob-
struction in the proximal segment of left anterior descending
artery (LAD), 80% obstruction in distal circumﬂex artery (Cx),
and 99% obstruction in middle right coronary artery (RCA)
(Fig. 1). Complete revascularization was achieved with 3 bare-
metal stents (3.0 mm  24 mm Liberte for LAD, 2.5 mm
 16 mm Liberte for Cx, and 2.75 mm  16 mm Liberte for
RCA) (Fig. 2). After removing the radial sheath, a compression
devicewas placed on thewrist and the patient was transferred
to CICU for follow-up.
Five hours after the procedure, the patient developed
severe chest pain with sudden onset, and her control ECG was
unremarkable. After a short while, her blood pressure dropped
to 85/50 mmHg, and bedside echocardiography revealed
pericardial effusion with cardiac tamponade.
An amount of 400 mL hemorrhagic pericardial ﬂuid was
removed by bedside pericardiocentesis. Hemodynamic status
of the patient rapidly improved, and her chest pain resolved.
Analysis of the pericardial ﬂuid conﬁrmed hemopericardium.
During the 2 days follow-up, no additional ﬂuid was drained
from the catheter. After conﬁrmation of absence of residual
pericardial effusion, the sheath in the pericardial cavity wasic images of the patient.
[(Fig._2)TD$FIG]
Fig. 2 – Coronary angiographic images of the patient after revascularization.
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revealed normal results for antinuclear antibodies, antipho-
spholipid IgG and IgM, anticardiolipin IgG and IgM, viral
markers, folic acid, B12 vitamin, and thyroid function tests.
Thoracoabdominal computed tomography was performed for
malignancy scanning. No solid tumoral inﬁltrations or
pathological lymph nodes were detected. A diagnosis of ES
was concluded by hematologists based on ruling out other
possible etiologies.
The patient was discharged on the sixth day of admission
with laboratory ﬁndings showing a blood count with WBC
9.81  103/mL, hemoglobin 9.1 g/dL, platelet count 55  103/mL,
and a prescription of aspirin (100 mg po daily), clopidogrel
(75 mgpodaily), andmethyl prednisolone (70 mgpodaily). She
was asymptomatic onher follow-up visit at 1month.Her blood
tests revealed WBC 6.7  103/mL, hemoglobin 12.6 g/dL, and
platelet count 123  103/mL. She remains asymptomatic on her
follow-up visits.
3. DiscussionDiagnosis of ES is established by ruling out similar conditions
like systemic lupus erythematosus, lymphoproliferative
disorders, primary immunodeﬁciency, and thrombotic throm-
bocytopenic purpura. Careful analysis of the tests and
examination is crucial for avoiding misdiagnosis.8 Peripheral
blood smear is substantial for diagnosis of both lymphopro-
liferative disorders and thrombotic thrombocytopenic purpu-
ra. Bonemarrowbiopsymight be necessary for diagnosiswhen
ﬁndings of peripheral blood smear are consistent with
lymphoproliferative disorders.9
Since ES is a rare autoimmune disorder, there are no
systematic or randomized studies for ES treatment, and
current treatment is mainly based on AIHA and ITP therapies.
First-line treatment commonly consists of glucocorticoids
and/or IVIG. Current practice institutes prednisolone (1–2 mg/
kg/day) and/or IVIG (0.4 g/kg/d for 4 days) in cases of remission
or ineffective prednisolone treatment. Immunosuppressive
agents or splenectomy are recommended as second-line
therapy for patients with relapse or worsening health
condition despite ﬁrst-line therapy.10NSTEMI is the most common form of acute coronary
syndromes, and also associated with high mortality rates.
Early treatment is crucial for the favorable prognosis of the
disease.11
In conditions associated with high bleeding risk as seen in
our case, medical treatment and interventional treatment are
both challenging. In order to minimize bleeding risk in our
patient, we initiated thrombocyte transfusion, corticosteroid
therapy, and IVIG for two days and then scheduled the patient
for percutaneous coronary intervention (PCI). Moreover, we
preferred radial access for CCA and PCI to minimize the
bleeding risk. The guidewire (ChoICE Floppy Guide Wire,
Boston Scientiﬁc), which was used to cross coronary lesions,
was not stiff. Bare metal stents were preferred to avoid long-
term dual antiplatelet therapy, and thus increased bleeding
risk. NSTEMI treatment includes antiaggregant and anticoag-
ulant drugs; however, in daily practice, hemopericardium is
not an expected complication in patients receiving those drugs
and undergoing PCI. In our patient, although the PCI procedure
was uneventful and revascularization was achieved success-
fully, cardiac tamponade occurred due to hemopericardium
5 h after the procedure. Prompt recognition of hemodynamic
compromise was life-saving at this stage. It is likely that
medical treatment facilitated bleeding event in this patient;
however, tendency for bleeding induced by ES might have
played a bigger role in the formation of a serious hemorrhagic
complication such as hemopericardium. Coronary rupture
inducedwithmicro-injury in coronary artery wall by the distal
tip of the guidewire during PCI combined with the bleeding
disorder of the patient may have led to hemopericardium.
Besides, administration of UFH during PCI to avoid thrombosis
may also have contributed to hemopericardium formation.
Perhaps fondaparinux could have been utilized instead of UFH
in order to decrease bleeding complications.
ES most commonly presents with bleeding events; howev-
er, it may rarely present with thrombosis. Although uncom-
mon, coexistence of ES and thrombotic events such as acute
coronary syndrome is associated with high morbidity and
mortality, and early reperfusion therapy is crucial in this
setting. When ES is seen with a high-mortality linked
condition such as acute coronary syndrome where early
reperfusion (medical or interventional) is crucial, the patient
i n d i a n h e a r t j o u rn a l 6 8 ( 2 0 1 6 ) s 2 8 0 – s 2 8 3 S283should be closely monitored during the diagnostic and
treatment period in order to achieve early recognition and
treatment of complications.
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